Institut Curie

Institut Curie is the leading cancer research and treatment centre in France and has been a recognised public utility foundation since 1921. Since its creation by Marie Curie, Institut Curie has worked on three missions: care, research and transmission.

Leiden University

The Leiden Institute of Chemistry (LIC) at the Leiden University is the basis for research and collaborations of the Leiden chemistry groups. Chemistry is the central science enabling a healthy future in a sustainable society. Chemistry researchers at Leiden University take a fundamental approach in finding tailored solutions for complex societal problems in human health and environmental issues.


LUMC strongly underpins the idea that ‘Science is the driving force behind innovative healthcare’. Outcomes of top level fundamental, translational and clinical research by LUMC researchers form a strong basis for innovative and qualitative healthcare on a national, European and international level. A real game changer was the development of the Dutch national research agenda (NWA) in 2015. The agenda reveals the complexity of the issues challenging Dutch society today. These issues are clustered in so called routes. LUMC is involved in many of these routes and contributes this way to solving important societal challenges.


Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea. The company is based in Italy. Up to 2023, the company has been focused on the pre-clinical activities related to the development of minimally invasive GROSSO® Implant, the first-ever nitinol corneal implant to restore the physiological curvature of the cornea with clear and predictable clinical outcomes in patients with keratoconus, a progressive eye disease causing distorted vision. The company is now approaching the first clinical trial for the GROSSO® Implant. The company is working to expand the core nitinol platform technology behind the GROSSO Implant to new therapeutic solutions in the pipeline for treating diseases of the eye and beyond in line with Recornea’s vision.